NP / PA
Bowling Green-Warren County Community Hospital Corporation
Bowling Green-Warren County Community Hospital Corporation was paid $13.47M by Medicaid between Jan 2018 and Dec 2024, across 112 billing codes. Its largest line is 99284, emergency room visit (serious) — 25% of everything it billed.
33Billing provider infoBOWLING GREEN-WARREN COUNTY COMMUNITY HOSPITAL CORPORATION
HORSE CAVE, KY 42749
HORSE CAVE, KY 42749
33aNPI1356716575assigned 12/14/2015
33bProvider typeCertified Registered Nurse Anesthetist
28Total paid$13.47M
24GClaims230,515
24DCodes billed112
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Certified Registered Nurse Anesthetist providers in Kentucky
Rank by total paid#3 of 53
Median peer was paid$84K
This provider vs. median161×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official LAWLESS, MICHELE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 32,404 | $1.69M | |
| 2019 | 33,155 | $1.52M | |
| 2020 | 31,821 | $1.80M | |
| 2021 | 35,729 | $2.14M | |
| 2022 | 34,303 | $2.11M | |
| 2023 | 36,330 | $2.25M | |
| 2024incomplete | 26,773 | $1.95M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 25% | 11,006 | 9,052 | $3.35M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 16% | 11,213 | 9,796 | $2.16M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 11% | 4,235 | 2,822 | $1.49M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 7.5% | 2,144 | 1,763 | $1.01M |
| 70450 | Computed tomography, head or brain; without contrast material | 3.9% | 1,666 | 1,265 | $522K |
| 36415 | Collection of venous blood by venipuncture | 2.6% | 38,918 | 15,967 | $357K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.4% | 5,717 | 1,119 | $323K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.4% | 272 | 247 | $322K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 2.1% | 3,976 | 3,456 | $287K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.9% | 6,173 | 4,604 | $256K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.8% | 3,457 | 2,925 | $244K |
| 71046 | Radiologic examination, chest; 2 views | 1.8% | 3,122 | 2,526 | $242K |
100 more codes
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.6% | 2,510 | $216K |
| 80053 | Comprehensive metabolic panel | 1.4% | 20,187 | $194K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.4% | 4,208 | $183K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.3% | 1,402 | $175K |
| 71045 | Radiologic examination, chest; single view | 1.2% | 3,076 | $156K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 17,561 | $127K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 3,406 | $123K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,890 | $98K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 3,116 | $97K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 490 | $77K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 5,086 | $76K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 982 | $74K |
| 72100 | <1% | 810 | $72K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 782 | $72K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,518 | $65K |
| 80061 | Lipid panel | <1% | 3,736 | $58K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 702 | $49K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 3,445 | $48K |
| 73630 | <1% | 487 | $47K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,624 | $45K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,408 | $42K |
| 73030 | <1% | 437 | $40K | |
| 82607 | <1% | 2,818 | $38K | |
| 80306 | <1% | 2,452 | $35K | |
| 84484 | <1% | 3,164 | $33K | |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 1,021 | $30K |
| 73610 | <1% | 297 | $29K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,417 | $29K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,231 | $29K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 266 | $28K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,208 | $27K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 499 | $26K |
| 73562 | <1% | 242 | $24K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,775 | $24K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,824 | $23K |
| 84703 | <1% | 2,843 | $23K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,896 | $21K |
| 71250 | <1% | 74 | $20K | |
| 83690 | <1% | 2,894 | $20K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 294 | $20K |
| 73130 | <1% | 190 | $19K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,936 | $19K |
| 87081 | <1% | 1,516 | $14K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,120 | $14K |
| 81003 | <1% | 2,975 | $14K | |
| 82746 | <1% | 1,099 | $14K | |
| 74018 | <1% | 135 | $13K | |
| 83880 | <1% | 436 | $12K | |
| 81001 | <1% | 2,437 | $10K | |
| 84439 | <1% | 1,362 | $10K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 581 | $10K |
| 87631 | <1% | 82 | $9K | |
| 83605 | <1% | 879 | $9K | |
| 72040 | <1% | 84 | $9K | |
| G0378 | Hospital observation service, per hour | <1% | 40 | $8K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 599 | $8K |
| 83735 | <1% | 1,420 | $8K | |
| 82553 | <1% | 567 | $7K | |
| 82550 | <1% | 907 | $6K | |
| 82728 | <1% | 494 | $6K | |
| 85610 | <1% | 1,655 | $6K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 414 | $5K |
| 95886 | <1% | 32 | $5K | |
| 81015 | <1% | 1,137 | $5K | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 528 | $4K |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 231 | $4K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 150 | $4K |
| 82150 | <1% | 523 | $3K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 96 | $3K |
| 73110 | <1% | 36 | $3K | |
| 90715 | <1% | 109 | $3K | |
| 85730 | <1% | 558 | $3K | |
| 85379 | <1% | 254 | $3K | |
| 87040 | <1% | 116 | $2K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 14 | $2K |
| 94664 | <1% | 126 | $2K | |
| 80074 | <1% | 29 | $2K | |
| 83540 | <1% | 324 | $2K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 98 | $2K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 44 | $2K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 23 | $2K |
| 87186 | <1% | 189 | $1K | |
| 83550 | <1% | 167 | $1K | |
| J3490 | Unclassified drugs | <1% | 109 | $1K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 63 | $1K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 57 | $1K |
| 86140 | <1% | 151 | $727.93 | |
| L4387 | Walking boot, non-pneumatic, with or without joints, with or without interface material, prefabricated, off-the-shelf | <1% | 13 | $720.00 |
| 82948 | <1% | 68 | $656.68 | |
| J2704 | Injection, propofol, 10 mg | <1% | 19 | $535.40 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 30 | $462.17 |
| 87088 | <1% | 61 | $448.55 | |
| 80050 | General health panel | <1% | 17 | $441.51 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 34 | $440.04 |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 19 | $296.26 |
| 85651 | <1% | 83 | $271.18 | |
| 82043 | <1% | 48 | $227.60 | |
| 82570 | <1% | 14 | $80.75 | |
| 3044F | <1% | 27 | $58.23 | |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 13 | $0.05 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLAWLESS, MICHELE (EXECUTIVE VICE PRESIDENT/CFO)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.